Atreca and Dana-Farber to partner on cancer immunotherapy

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Atreca, Inc., a biotechnology company focused on developing novel therapeutics based on a deep understanding of the human immune response, and the Dana-Farber Cancer Institute announced today that they have entered into a collaborative research agreement to focus Atreca’s IRC™ technology on the active immune responses of cancer patients whose disease is responding well to immunotherapy and other treatments. The research will apply Atreca’s Immune Repertoire Capture® (IRC™) technology, which identifies and generates sequences of functional, native antibodies and T cell receptors (TCRs) from active human immune responses.

A team of scientists led by F. Stephen Hodi, M.D., Director of the Melanoma Center and Center for Immuno-Oncology at Dana-Farber Cancer Institute/Brigham and Women's Cancer Center and Professor of Medicine at Harvard Medical School, will collaborate with Atreca to study how different immunotherapies generate an active immune response, to understand why only a subset of patients benefit from therapy, and to identify anti-tumor antibodies generated in these responses. The study will focus on patients with melanoma, non-small cell lung cancer (NSCLC), and renal cell cancer, with the potential to expand into other cancer types.

Read the press release at Business Wire